NAT10 Inhibition Shows Promise for Reproductive Health
A newly identified biological pathway linking RNA modification to follicle loss could inform future fertility treatments.
Updated on Oct. 25, 2026 in Biotech
Researchers have identified the NAT10 protein as a key driver of follicular atresia, the process of ovarian follicle degeneration in mammals. The study, published October 25, 2026, demonstrates that the NAT10 inhibitor Remodelin can reduce this degradation and improve reproductive efficiency in research models.
Why it matters
Identifying NAT10 as a mechanism of ovarian dysfunction provides a new target for treating infertility. This research clarifies the molecular pathway by which oxidative stress leads to follicle loss, potentially opening the door to pharmacological interventions for reproductive health.
The study measured elevated ac4C RNA modifications linked to NAT10 expression in degenerating follicles compared to healthy ones. These modifications increase Tnc mRNA stability, which subsequently triggers the degradation of Parkin and inhibits mitophagy.
The players
Remodelin
A small-molecule compound that functions as a specific inhibitor of the NAT10 enzyme.
NAT10
An acetyltransferase protein that catalyzes RNA modifications and influences mRNA stability.
The details
NAT10 acts as a catalytic enzyme that adds ac4C (N4-acetylcytidine) modifications to Tnc mRNA, effectively stabilizing the molecule. The resulting Tnc protein promotes the ubiquitination—a process of marking proteins for destruction—and degradation of Parkin. Because Parkin is essential for mitophagy—the cellular process of clearing out damaged mitochondria—its loss induces oxidative stress that drives follicular atresia. Remodelin serves as a specific small-molecule inhibitor of NAT10 activity.
Timeline
October 25, 2026: The research findings were published.
The Tech Race
This work connects RNA modification research with the broader field of reproductive medicine and aging. It specifically isolates the NAT10 pathway as a critical lever for managing mitochondrial health in ovarian tissue.
This research is in the preclinical phase and is not currently available for clinical use or fertility treatments. Future developments will depend on determining if Remodelin or similar compounds can safely inhibit NAT10 in human reproductive applications.
The takeaway
The study establishes a clear link between RNA modification, mitochondrial health, and ovarian function. Researchers and clinicians should track upcoming studies on NAT10 inhibitors to see if these preclinical results can be translated into viable treatments for subfertility.
Further reading
For more developments in this field, visit our Biotech section.
Source note: This article includes information reported by Nature.
